Chubachi A, Miura A B, Yamaguchi A, Nishimura S
3rd. Dept. of Internal Medicine, Akita University, School of Medicine.
Gan To Kagaku Ryoho. 1988 Jul;15(7):2057-63.
Thirty-seven previously untreated patients with advanced non-Hodgkin's lymphoma were treated with VEPA therapy. The complete remission (CR) rate was higher in the patients with diffuse B-cell lymphoma (75%) than in those with follicular B-cell lymphoma (20%) and T-cell lymphoma (42%). Two characteristics, i.e., elevated LDH and bone marrow involvement, were negatively associated with response rate in patients with diffuse lymphoma (B-, T-). The median duration of CR has not yet been reached, and the 2-year relapse-free rate was 64% for cases of diffuse B-cell lymphoma, while for T-cell lymphoma patients, the median duration of CR was 7 months. For diffuse B-cell lymphoma patients, the median survival has not yet been reached, and the 2-year survival rate was 57%. On the other hand, median survival for T-cell lymphoma patients was 12 months. VEPA therapy was less effective for the treatment of T-cell lymphoma, and a more intensive regimen should therefore be designed to overcome the potential aggressiveness of T-cell lymphoma.
37例先前未经治疗的晚期非霍奇金淋巴瘤患者接受了VEPA疗法。弥漫性B细胞淋巴瘤患者的完全缓解（CR）率（75%）高于滤泡性B细胞淋巴瘤患者（20%）和T细胞淋巴瘤患者（42%）。两个特征，即乳酸脱氢酶（LDH）升高和骨髓受累，与弥漫性淋巴瘤（B细胞、T细胞）患者的缓解率呈负相关。CR的中位持续时间尚未达到，弥漫性B细胞淋巴瘤病例的2年无复发生存率为64%，而T细胞淋巴瘤患者CR的中位持续时间为7个月。对于弥漫性B细胞淋巴瘤患者，中位生存期尚未达到，2年生存率为57%。另一方面，T细胞淋巴瘤患者的中位生存期为12个月。VEPA疗法对T细胞淋巴瘤的治疗效果较差，因此应设计更强化的方案以克服T细胞淋巴瘤的潜在侵袭性。
